88 phenotypes from 3 alleles in 6 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Relbshep/Relbshep A;C-Relbshep/GrsrJ	abnormal circulating protein level	J:171971
	anemia	J:171971
	decreased body size	J:171971
	decreased body weight	J:171971
	decreased circulating amylase level	J:171971
	decreased circulating serum albumin level	J:171971
	decreased circulating total protein level	J:171971
	decreased liver function	J:171971
	lethality at weaning, complete penetrance	J:171971
	liver cirrhosis	J:171971
	liver failure	J:171971
	liver inflammation	J:171971
	pale liver	J:171971
	preweaning lethality, incomplete penetrance	J:171971
	thin tail	J:171971
Relbtm1.1Fwei/Relbtm1.1Fwei Tg(Cd4-cre)1Cwi/0 involves: C57BL/6 * DBA/2	normal immune system phenotype	J:169863
Relbtm1.1Fwei/Relbtm1.1Fwei Tg(Lck-cre)I57Jxm/0 involves: ICR	abnormal gamma-delta T cell morphology	J:169863
	decreased interleukin-17 secretion	J:169863
	normal immune system phenotype	J:169863
	increased susceptibility to bacterial infection	J:169863
Relbtm1Brv/Relbtm1Brv either: (involves: 129S2/SvPas) or (involves: C57BL/6) or (involves: 129S2/SvPas * C57BL/6)	abnormal epidermis stratum corneum morphology	J:63950
	abnormal keratinocyte apoptosis	J:63950
	abnormal keratinocyte physiology	J:63950
	acanthosis	J:63950
	alopecia	J:63950
	dermatitis	J:63950
	epidermal hyperplasia	J:63950
	hyperkeratosis	J:63950
	increased eosinophil cell number	J:63950
	increased keratinocyte proliferation	J:63950
	increased respiratory mucosa goblet cell number	J:63950
	lung inflammation	J:63950
	mixed cellular infiltration to dermis	J:63950
	pathological neovascularization	J:63950
	reddish skin	J:63950
	scaly skin	J:63950
	thick dermal layer	J:63950
	thick epidermis	J:63950
	thick skin	J:63950
Relbtm1Brv/Relbtm1Brv involves: 129S2/SvPas	abnormal gamma-delta T cell morphology	J:169863
	decreased dendritic cell number	J:85808
	spleen hyperplasia	J:85808
Relbtm1Brv/Relbtm1Brv involves: 129S2/SvPas * C57BL/6	abnormal bile duct morphology	J:22675
	abnormal cell-mediated immunity	J:22675
	abnormal cytokine level	J:40630
	abnormal cytotoxic T cell physiology	J:40630
	abnormal definitive hematopoiesis	J:22675
	abnormal erythropoiesis	J:22675
	abnormal hepatobiliary system morphology	J:22675
	abnormal humoral immune response	J:40630
	abnormal immune system organ morphology	J:22675
	abnormal immune system physiology	J:22675, J:40630
	abnormal immunoglobulin level	J:40630
	abnormal interferon level	J:40630
	abnormal interleukin level	J:40630
	abnormal lymph node morphology	J:22675
	abnormal macrophage physiology	J:40630
	abnormal mesenteric lymph node morphology	J:22675
	abnormal proerythroblast morphology	J:22675
	abnormal tumor necrosis factor level	J:40630
	amyloidosis	J:22675
	decreased B cell proliferation	J:40630
	decreased dendritic cell number	J:22675
	decreased spleen white pulp amount	J:22675
	decreased susceptibility to type IV hypersensitivity reaction	J:22675
	decreased T cell number	J:22675
	disheveled coat	J:22675
	distended abdomen	J:22675
	epididymis inflammation	J:22675
	extramedullary hematopoiesis	J:22675
	hunched posture	J:22675
	impaired neutrophil phagocytosis	J:40630
	increased bone marrow cell number	J:22675
	increased IgE level	J:40630
	increased IgM level	J:40630
	increased spleen red pulp amount	J:22675
	increased spleen weight	J:22675
	increased susceptibility to bacterial infection	J:40630
	increased susceptibility to Riboviria infection	J:40630
	intestinal inflammation	J:22675
	liver fibrosis	J:22675
	liver inflammation	J:22675
	lung inflammation	J:22675
	myeloid hyperplasia	J:22675
	myositis	J:22675
	ovary inflammation	J:22675
	premature death	J:22675
	pulmonary alveolar hemorrhage	J:22675
	pulmonary fibrosis	J:22675
	reduced fertility	J:22675
	salivary gland inflammation	J:22675
	stomach inflammation	J:22675
	thymus atrophy	J:22675
	thymus hypoplasia	J:22675